FY2028 EPS Estimate for ImmunityBio Boosted by Analyst

ImmunityBio, Inc. (NASDAQ:IBRX) – HC Wainwright increased their FY2028 earnings per share (EPS) estimates for ImmunityBio in a research note issued to investors on Thursday, October 15th. HC Wainwright analyst A. Maldonado now expects that the company will earn $0.82 per share for the year, up from their prior estimate of $0.54. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for ImmunityBio’s FY2029 earnings at $1.22 EPS and FY2030 earnings at $1.87 EPS.

IBRX has been the subject of several other reports. Piper Sandler restated an “overweight” rating and set a $16.00 target price on shares of ImmunityBio in a research report on Wednesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. Finally, Jefferies Financial Group increased their price target on shares of ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $16.00.

ImmunityBio Trading Up 4.2%

IBRX opened at $8.77 on Monday. The company has a market cap of $9.29 billion, a price-to-earnings ratio of -9.04 and a beta of 0.02. The company’s 50 day moving average is $8.61 and its 200 day moving average is $7.99. ImmunityBio has a 12-month low of $1.95 and a 12-month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to analysts’ expectations of $49.70 million.

Institutional Investors Weigh In On ImmunityBio

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fortress Financial Solutions LLC bought a new position in ImmunityBio during the third quarter valued at approximately $105,000. Firethorn Wealth Partners LLC grew its holdings in ImmunityBio by 107.9% during the 3rd quarter. Firethorn Wealth Partners LLC now owns 25,475 shares of the company’s stock valued at $240,000 after buying an additional 13,219 shares in the last quarter. Courier Capital LLC grew its holdings in ImmunityBio by 100.0% during the 3rd quarter. Courier Capital LLC now owns 112,000 shares of the company’s stock valued at $1,057,000 after buying an additional 56,000 shares in the last quarter. GAMMA Investing LLC grew its holdings in ImmunityBio by 262.2% during the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after buying an additional 2,756 shares in the last quarter. Finally, Collective Family Office LLC increased its stake in ImmunityBio by 2.6% in the 3rd quarter. Collective Family Office LLC now owns 161,254 shares of the company’s stock worth $1,522,000 after acquiring an additional 4,054 shares during the last quarter. 8.58% of the stock is owned by institutional investors.

Insider Buying and Selling at ImmunityBio

In related news, Director Cheryl Cohen sold 81,056 shares of ImmunityBio stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the transaction, the director owned 100,309 shares in the company, valued at approximately $1,053,244.50. The trade was a 44.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the transaction, the director directly owned 2,777,788 shares of the company’s stock, valued at $29,861,221. This represents a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by company insiders.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.